Literature DB >> 22436293

Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.

Yuri Takano1, Takashi Ueyama, Fuminobu Ishikura.   

Abstract

BACKGROUND: We have reported that α and β adrenergic blockers could protect against emotional stress-induced cardiac dysfunction. Azelnidipine is a unique calcium blocker which does not increase heart rate. The purpose of this study is to evaluate the effect of azelnidipine to prevent stress-induced cardiac dysfunction. METHODS AND
RESULTS: Rats premedicated with azelnidipine (0.3 mg/kg), labetalol (3 mg/kg), or vehicle, were restrained for 30 min (immobilization stress: IMO) to reproduce emotional stress, and anesthetized to release stress. We measured the fractional area change (FAC) by echocardiography, blood pressure, and heart rate at the end of IMO and every 10 min for 60 min after IMO. During IMO, FAC in the labetalol group was significantly lower than that in the other two groups. At 20 min after IMO, FAC in the azelnidipine or labetalol group was significantly higher than that in the vehicle group (86 ± 9%, 73 ± 5% vs. 56 ± 11%, p<0.05). During IMO, mean blood pressure in the azelnidipine or labetalol group was significantly lower than that in the vehicle group (107 ± 5 mmHg, 106 ± 17 mmHg vs. 124 ± 5 mmHg, p<0.05).
CONCLUSION: Acute administration of azelnidipine could prevent a sudden drop of cardiac function after acute stress like IMO. Azelnidipine might have a protective effect on stress-induced cardiac dysfunction like α and β adrenergic blockers.
Copyright © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22436293     DOI: 10.1016/j.jjcc.2012.01.017

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  4 in total

1.  Amlodipine has a preventive effect on temporal left ventricular hypokinesia after emotional stress compared with an angiotensin II receptor blocker.

Authors:  Fuminobu Ishikura; Yuri Takano; Takashi Ueyama
Journal:  J Med Ultrason (2001)       Date:  2012-09-06       Impact factor: 1.314

2.  Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness.

Authors:  Shunsuke Kiuchi; Shinji Hisatake; Muneyasu Kawasaki; Osamu Hirashima; Takayuki Kabuki; Junichi Yamazaki; Takanori Ikeda
Journal:  Clin Pharmacol       Date:  2015-10-08

Review 3.  Takotsubo Syndrome: Translational Implications and Pathomechanisms.

Authors:  Xuehui Fan; Guoqiang Yang; Jacqueline Kowitz; Ibrahim Akin; Xiaobo Zhou; Ibrahim El-Battrawy
Journal:  Int J Mol Sci       Date:  2022-02-10       Impact factor: 5.923

4.  Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis.

Authors:  Ekaterina S Prokudina; Boris K Kurbatov; Konstantin V Zavadovsky; Alexander V Vrublevsky; Natalia V Naryzhnaya; Yuri B Lishmanov; Leonid N Maslov; Peter R Oeltgen
Journal:  Curr Cardiol Rev       Date:  2021
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.